LRRK2 and Parkinson disease: BIIB122 will also be assessed in a Phase 3 clinical trial NCT05418673, a multicenter, randomized, double-blind, placebo-controlled study of symptomatic Parkinson's disease patients carrying the LRRK2-GS mutation.